Tested on Gulf Medical Boards (DHA, SMLE, MOH & HAAD)
Clinical calculations and diagnostic scoring systems like MASCC Risk Index for Febrile Neutropenia frequently appear on Prometric exams. Master high-yield clinical vignettes with instant AI-powered pathophysiology rationales.
What is the MASCC Risk Index for Febrile Neutropenia?
The MASCC Risk Index for Febrile Neutropenia is an evidence-based clinical decision rule engineered to quantify diagnostic probability, stratify clinical severity, and guide therapeutic decision-making in oncology practice. The Multinational Association for Supportive Care in Cancer (MASCC) score identifies oncology patients presenting with chemotherapy-induced febrile neutropenia who have a low risk of medical complications (score ≥ 21), facilitating safe outpatient oral antibiotic management. Clinical scoring tools like MASCC Risk Index for Febrile Neutropenia are essential in acute and outpatient management, enabling clinicians to objectively differentiate between low-risk candidates suitable for conservative therapy and high-risk patients requiring urgent interventions. Verified against current 2026 clinical standards, this tool is extensively tested on Gulf health authority licensing exams including DHA (Dubai), SMLE (Saudi Arabia), MOH, HAAD/DOH (Abu Dhabi), OMSB (Oman), and QCHP (Qatar).
💡Clinical Pearls & Diagnostic Utility
Empowers oncologists and emergency physicians to safely select appropriate candidates for outpatient oral antimicrobial therapy versus urgent inpatient IV therapy.
Formula & Calculation Parameters
The mathematical equation and clinical variables required to calculate MASCC Risk Index for Febrile Neutropenia:
Score Interpretation & Clinical Stratification
| Score Range | Clinical Interpretation | Risk Tier |
|---|---|---|
| ≤ 20 | High Risk Febrile Neutropenia (< 21 pts) | red |
| ≥ 21 | Low Risk Febrile Neutropenia (≥ 21 pts) | green |
When to Exercise Caution
Not applicable to pediatric cancer patients; clinical judgment supersedes score if severe localized infection, hemodynamic compromise, or poor social support is present.
Clinical Review Board
Dr. Muhammad Nouman, MBBS
Capital Medical University | PMDC Reg No: 117744-P
Clinical Audit Status
✓ Verified for 2026 Guidelines
Last updated: 2026-08-08
Peer-Reviewed Medical Literature
- •Klastersky J, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038-3051.
- •Taplitz RA, et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol. 2018;36(14):1443-1453.
Related Oncology Calculators & Scoring Tools
Explore related clinical calculators, risk stratification indexes, and diagnostic scoring algorithms in Oncology:
Wells' Criteria for DVT
Calculates the pre-test probability of Deep Vein Thrombosis.
Glasgow Coma Scale (GCS)
Assesses the level of consciousness after neurological injury.
HAS-BLED Score
Assesses bleeding risk in patients on anticoagulation therapy.
qSOFA Score
Quick Sequential Organ Failure Assessment for sepsis risk.
Centor Score
Estimates probability of streptococcal pharyngitis.
Mean Arterial Pressure (MAP)
Calculate MAP based on Systolic and Diastolic Blood Pressure.
Gulf Medical Licensing & Prometric Exam Preparation Network
Clinical calculations like MASCC Risk Index for Febrile Neutropenia are essential knowledge across Gulf health licensing authorities. Review official exam blueprints, verify pass marks (SMLE: 70%), and access free practice test engines: